Despite the setback that Merck faced in its Keynote-183 and Keynote-185 trials recently, its cancer drug Keytruda hasn’t lost its momentum this year. To add to that, Merck’s newly launched hepatitis C drug Zepatier and established HPV vaccine Gardasil have been gaining ground.
from Forbes Real Time http://www.forbes.com/sites/greatspeculations/2017/08/22/merck-maintaining-its-lofty-valuation-due-to-keytruda-momentum/
via IFTTT
No comments:
Post a Comment